Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT
Company Participants
Janet Hammond – Chief Development Officer
Maria Horga – Chief Medical Officer
John Vavricka – Chief Commercial Officer
Andrea Corcoran – CFO, Executive VP of Legal & Secretary
Conference Call Participants
Maxwell Skor – Morgan Stanley, Research Division
Presentation
Maxwell Skor
Equity Analyst
Great. Hello, everyone. I’m Max Skor with Morgan Stanley. And before we get started, I’m just going to read a quick disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. So with that, I’d like to introduce the Atea team. Very happy to have everyone here. And maybe just to level set, could you introduce the Atea story to people in the audience who maybe aren’t as familiar.
Janet Hammond
Chief Development Officer
Yes, so Atea is a biotech company based in Boston, and we have a nucleoside platform, which we have been using against serious viral diseases. We had a trial in COVID, and we are currently in Phase III with our nucleoside analog bemnifosbuvir for hepatitis C.
Question-and-Answer Session
Maxwell Skor
Morgan Stanley, Research Division
Great. So yes, 2 ongoing Phase III trials. But maybe can we discuss a bit deeper, what’s the core scientific rationale behind your regimen? And how does it aim to improve on the current standard of care for hep C?
Janet Hammond
Chief Development Officer
So I think it’s a bit underappreciated, but the direct factoring antivirals that are commonly used for hepatitis C were approved about 10 years ago. And today, there are over 50 million people still with hepatitis C around the world. And within the U.S., about 2.4 million to 4 million people are estimated to have
#Atea #Pharmaceuticals #AVIR #Presents #Morgan #Stanley #23rd #Annual #Global